← Back to Search

Hormone Therapy

C-peptide for Low Blood Sugar

Phase < 1
Waitlist Available
Led By Jason Winnick, PhD
Research Sponsored by University of Cincinnati
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Must not have
Presence of hepatitis
Presence of HIV
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during procedure, up to 2.5 hours

Summary

This trial aims to study the effects of a protein called C-peptide on glucagon secretion during insulin-induced hypoglycemia in dogs. The findings from this study could help in understanding how C

Who is the study for?
This trial is for individuals with type 1 diabetes who have a body mass index (BMI) under 30. It's not open to pregnant or breastfeeding women, smokers, or those with HIV, hepatitis, cardiovascular disease, or microvascular complications.
What is being tested?
The study investigates whether C-peptide can help prevent severe low blood sugar in people with type 1 diabetes by increasing glucagon secretion and liver glucose production. Participants will receive either C-peptide or saline as a comparison.
What are the potential side effects?
Potential side effects are not explicitly listed but may include reactions at the injection site and possible unknown risks associated with administering C-peptide.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have hepatitis.
Select...
I am HIV positive.
Select...
I have a heart condition.
Select...
I have small blood vessel disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during procedure, up to 2.5 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and during procedure, up to 2.5 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Glucagon
Glucose infusion rate
Hepatic glucose production
Secondary study objectives
C-peptide
cortisol
epinephrine
+1 more

Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: Healthy Control- C-peptideActive Control1 Intervention
C-peptide will be infused in healthy control subjects during insulin-induced hypoglycemia
Group II: T1D- C-peptideActive Control1 Intervention
C-peptide will be infused in T1D subjects during insulin-induced hypoglycemia
Group III: Healthy Control- SalinePlacebo Group1 Intervention
Saline will be infused in healthy control subjects during insulin-induced hypoglycemia
Group IV: T1D- SalinePlacebo Group1 Intervention
Saline will be infused in T1D subjects during insulin-induced hypoglycemia

Find a Location

Who is running the clinical trial?

University of CincinnatiLead Sponsor
436 Previous Clinical Trials
635,324 Total Patients Enrolled
Jason Winnick, PhDPrincipal InvestigatorUniversity of Cincinnati
3 Previous Clinical Trials
121 Total Patients Enrolled
~25 spots leftby Jun 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top